Peripheral Klotho Fragment Improves Brain Resilience in Aging and Parkinson’s Models

A 2024 study demonstrates that higher cerebrospinal fluid klotho levels correlate with better cognition in people with Parkinson’s, suggesting klotho may be a biomarker or therapeutic target.

This 2024 study reveals that carriers of the KL-VS variant exhibit lower levels of neuroinflammatory and synaptic degeneration markers, indicating a potential resilience mechanism against age-related cognitive decline.

A 2023 Nature Aging study shows that low-dose klotho administration improves cognition in aging rhesus macaques, supporting translational potential for age-related cognitive decline in humans.

This 2022 study finds that APOE4 carriers have lower serum klotho levels, helping explain increased Alzheimer’s vulnerability and offering insight into the gene-environment interaction in brain aging.

This 2021 Neurobiology of Aging meta-analysis finds that carriers of the KL-VS genetic variant show reduced brain amyloid burden, especially in those with APOE4, suggesting a protective role in Alzheimer’s risk.

A 2017 study in Cell Reports shows that peripheral delivery of a klotho protein fragment enhances cognition and neural resilience in young, aging, and α-synuclein transgenic mice, despite not crossing the blood-brain barrier.

This 2015 Journal of Neuroscience study demonstrates that systemic klotho treatment improves learning and memory in a mouse model of Alzheimer’s, revealing potential for neurodegenerative therapy.